Home » Newsletters » BioWorld Science

BioWorld Science

March 25, 2022

View Archived Issues

"Trojan horse" approach redirects tetanus immune response to tumors

Researchers unveil novel markers of GABA catabolism pathway abnormalities

Roche patents compounds for Gram-negative bacterial infections

German researchers divulge nitric oxide production inhibitors

Medshine Discovery presents new antifungal compounds

Gasherbrum Bio identifies GLP-1 receptor agonists

Aubrak Therapeutics patents new PROTACs for cancer

Regulus miR-155 inhibitors studied to treat ALS

Chugai gains access to Halozyme's ENHANZE drug delivery technology

BiondVax collaborates with Max Planck and UMG for development of NanoAbs

Insilico Medicine and EQRx enter drug discovery and development collaboration

PPARgamma isoforms have specific and separable roles in gene regulation and metabolism

Predictive Oncology validates Discovery 21 results

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...